BIOMAT Database Logo BIOMAT Database Logo

Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler versus MDI. 2010

R Zuwallack, and M C De Salvo, and T Kaelin, and E D Bateman, and C S Park, and R Abrahams, and F Fakih, and P Sachs, and K Pudi, and Y Zhao, and C C Wood, and
St. Francis Hospital Medical Center, Hartford, CT 06105, USA. rzuwalla@stfranciscare.org

We compared the efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler, a novel propellant-free inhaler, versus chlorofluorocarbon (CFC)-metered dose inhaler (MDI) and ipratropium Respimat inhaler in patients with COPD. This was a multinational, randomized, double-blind, double-dummy, 12-week, parallel-group, active-controlled study. Patients with moderate to severe COPD were randomized to ipratropium bromide/albuterol (20/100mcg) Respimat inhaler, ipratropium bromide/albuterol MDI [36mcg/206mcg (Combivent Inhalation Aerosol MDI)], or ipratropium bromide (20mcg) Respimat inhaler. Each medication was administered four times daily. Serial spirometry was performed over 6h (0.15min, then hourly) on 4 test days. The primary efficacy variable was forced expiratory volume in 1s (FEV(1)) change from test day baseline at 12 weeks. A total of 1209 of 1480 randomized, treated patients completed the study; the majority were male (65%) with a mean age of 64 yrs and a mean screening pre-bronchodilator FEV(1) (percent predicted) of 41%. Ipratropium bromide/albuterol Respimat inhaler had comparable efficacy to ipratropium bromide/albuterol MDI for FEV(1) area under the curve at 0-6h (AUC(0-6)), superior efficacy to ipratropium Respimat inhaler for FEV(1) AUC(0-4) and comparable efficacy to ipratropium Respimat inhaler for FEV(1) AUC(4-6). All active treatments were well tolerated. This study demonstrates that ipratropium bromide/albuterol 20/100mcg inhaler administered four times daily for 12 weeks had equivalent bronchodilator efficacy and comparable safety to ipratropium bromide/albuterol 36mcg/206mcg MDI, and significantly improved lung function compared with the mono-component ipratropium bromide 20 mcg Respimat inhaler. [Clinical Trial Identifier Number: NCT00400153].

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009241 Ipratropium A muscarinic antagonist structurally related to ATROPINE but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic. N-Isopropylatropine,(endo,syn)-(+-)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane,Atrovent,Ipratropium Bromide,Ipratropium Bromide Anhydrous,Ipratropium Bromide Monohydrate,Ipratropium Bromide, (endo,anti)-Isomer,Ipratropium Bromide, (exo,syn)-Isomer,Ipratropium Bromide, endo-Isomer,Itrop,Sch-1000,Sch-1178,N Isopropylatropine,Sch 1000,Sch 1178,Sch1000,Sch1178
D009330 Nebulizers and Vaporizers Devices that cause a liquid or solid to be converted into an aerosol (spray) or a vapor. It is used in drug administration by inhalation, humidification of ambient air, and in certain analytical instruments. Atomizers,Inhalation Devices,Inhalators,Inhalers,Vaporizers,Nebulizers,Vaporizers and Nebulizers,Atomizer,Device, Inhalation,Devices, Inhalation,Inhalation Device,Inhalator,Inhaler,Nebulizer,Vaporizer
D012129 Respiratory Function Tests Measurement of the various processes involved in the act of respiration: inspiration, expiration, oxygen and carbon dioxide exchange, lung volume and compliance, etc. Lung Function Tests,Pulmonary Function Tests,Function Test, Pulmonary,Function Tests, Pulmonary,Pulmonary Function Test,Test, Pulmonary Function,Tests, Pulmonary Function,Function Test, Lung,Function Test, Respiratory,Function Tests, Lung,Function Tests, Respiratory,Lung Function Test,Respiratory Function Test,Test, Lung Function,Test, Respiratory Function,Tests, Lung Function,Tests, Respiratory Function
D001993 Bronchodilator Agents Agents that cause an increase in the expansion of a bronchus or bronchial tubes. Bronchial-Dilating Agents,Bronchodilator,Bronchodilator Agent,Broncholytic Agent,Bronchodilator Effect,Bronchodilator Effects,Bronchodilators,Broncholytic Agents,Broncholytic Effect,Broncholytic Effects,Agent, Bronchodilator,Agent, Broncholytic,Agents, Bronchial-Dilating,Agents, Bronchodilator,Agents, Broncholytic,Bronchial Dilating Agents,Effect, Bronchodilator,Effect, Broncholytic,Effects, Bronchodilator,Effects, Broncholytic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D005541 Forced Expiratory Volume Measure of the maximum amount of air that can be expelled in a given number of seconds during a FORCED VITAL CAPACITY determination . It is usually given as FEV followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity. Forced Vital Capacity, Timed,Timed Vital Capacity,Vital Capacity, Timed,FEVt,Capacities, Timed Vital,Capacity, Timed Vital,Expiratory Volume, Forced,Expiratory Volumes, Forced,Forced Expiratory Volumes,Timed Vital Capacities,Vital Capacities, Timed,Volume, Forced Expiratory,Volumes, Forced Expiratory
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

R Zuwallack, and M C De Salvo, and T Kaelin, and E D Bateman, and C S Park, and R Abrahams, and F Fakih, and P Sachs, and K Pudi, and Y Zhao, and C C Wood, and
COPD patient satisfaction with ipratropium bromide/albuterol delivered via Respimat: a randomized, controlled study.
January 2013, International journal of chronic obstructive pulmonary disease,
R Zuwallack, and M C De Salvo, and T Kaelin, and E D Bateman, and C S Park, and R Abrahams, and F Fakih, and P Sachs, and K Pudi, and Y Zhao, and C C Wood, and
Albuterol delivered by metered-dose inhaler (MDI), MDI with spacer, and Rotahaler device--a comparison of efficacy and safety.
January 1998, The Journal of asthma : official journal of the Association for the Care of Asthma,
R Zuwallack, and M C De Salvo, and T Kaelin, and E D Bateman, and C S Park, and R Abrahams, and F Fakih, and P Sachs, and K Pudi, and Y Zhao, and C C Wood, and
Long-Term Efficacy and Safety of Ipratropium Bromide plus Fenoterol via Respimat((R)) Soft Misttrade mark Inhaler (SMI) versus a Pressurised Metered-Dose Inhaler in Asthma.
January 2004, Clinical drug investigation,
R Zuwallack, and M C De Salvo, and T Kaelin, and E D Bateman, and C S Park, and R Abrahams, and F Fakih, and P Sachs, and K Pudi, and Y Zhao, and C C Wood, and
Efficiency of Ipratropium Bromide and Albuterol Deposition in the Lung Delivered via a Soft Mist Inhaler or Chlorofluorocarbon Metered-Dose Inhaler.
April 2016, Clinical and translational science,
R Zuwallack, and M C De Salvo, and T Kaelin, and E D Bateman, and C S Park, and R Abrahams, and F Fakih, and P Sachs, and K Pudi, and Y Zhao, and C C Wood, and
Efficacy and safety of ipratropium bromide plus fenoterol inhaled via Respimat Soft Mist Inhaler vs. a conventional metered dose inhaler plus spacer in children with asthma.
March 2004, Pediatric pulmonology,
R Zuwallack, and M C De Salvo, and T Kaelin, and E D Bateman, and C S Park, and R Abrahams, and F Fakih, and P Sachs, and K Pudi, and Y Zhao, and C C Wood, and
Clinical efficacy and safety of the combination of ipratropium bromide and fenoterol inhaled via the Respimat Soft Mist inhaler for relief of airflow obstruction.
February 2008, Expert review of respiratory medicine,
R Zuwallack, and M C De Salvo, and T Kaelin, and E D Bateman, and C S Park, and R Abrahams, and F Fakih, and P Sachs, and K Pudi, and Y Zhao, and C C Wood, and
A review of ipratropium bromide/fenoterol hydrobromide (Berodual) delivered via Respimat Soft Mist Inhaler in patients with asthma and chronic obstructive pulmonary disease.
January 2004, Drugs,
R Zuwallack, and M C De Salvo, and T Kaelin, and E D Bateman, and C S Park, and R Abrahams, and F Fakih, and P Sachs, and K Pudi, and Y Zhao, and C C Wood, and
A prospective controlled trial of albuterol aerosol delivered via metered dose inhaler-spacer device (MDI) versus jet nebulizer in ventilated preterm neonates.
May 2001, American journal of perinatology,
R Zuwallack, and M C De Salvo, and T Kaelin, and E D Bateman, and C S Park, and R Abrahams, and F Fakih, and P Sachs, and K Pudi, and Y Zhao, and C C Wood, and
Improved delivery of ipratropium bromide/fenoterol from Respimat Soft Mist Inhaler in patients with COPD.
May 2004, Respiratory medicine,
R Zuwallack, and M C De Salvo, and T Kaelin, and E D Bateman, and C S Park, and R Abrahams, and F Fakih, and P Sachs, and K Pudi, and Y Zhao, and C C Wood, and
Clinical comparability of albuterol delivered by the breath-actuated inhaler (Spiros) and albuterol by MDI in patients with asthma.
April 1999, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology,
Copied contents to your clipboard!